Table 5. Cumulative dose of azathioprine for secondary cancer development in patients with allogeneic HSCT.
|
Univariate analysis |
Multivariate analysisa |
|||
|---|---|---|---|---|
| Variables | HR (95% CI) | P-value | HR (95% CI) | P-value |
|
Azathioprineb | ||||
| Non-use | Reference | Reference | ||
| <15 100 mg | 2.67 (0.96–7.40) | 0.060 | 2.51 (0.90–6.99) | 0.079 |
| ⩾15 100 mg | 3.68 (1.42–9.51) | 0.007 | 3.58 (1.37–9.38) | 0.010 |
| Dose–response relationship | 1.97 (1.26–3.09) | 0.003 | 1.94 (1.22–3.07) | 0.005 |
Abbreviations: CI=confidence interval; HSCT=haematopoietic stem cell transplantation; HR=hazard ratio.
a
Azathioprine was analysed as a time-dependent covariate in the Cox regression model and adjusted with variables listed in Table 4 multivariate analysis.
b
With cutoff points at non-use and the 50th percentile of cumulative dose.